Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41

1.

Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study.

Morsica G, Bagaglio S, Spagnuolo V, Castagna A, Di Serio C, Galli A, Della Torre L, Andolina A, Pramov A, Uberti-Foppa C.

PLoS One. 2017 Sep 1;12(9):e0184128. doi: 10.1371/journal.pone.0184128. eCollection 2017.

2.

Towards the development of a wearable Electrical Impedance Tomography system: A study about the suitability of a low power bioimpedance front-end.

Menolotto M, Rossi S, Dario P, Della Torre L.

Conf Proc IEEE Eng Med Biol Soc. 2015;2015:3133-6. doi: 10.1109/EMBC.2015.7319056.

PMID:
26736956
3.

Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.

Nozza S, Galli L, Antinori A, Chiappetta S, Mazzotta F, Zaccarelli M, Ottou S, De Battista D, Pogliaghi M, Di Pietro M, Malnati M, Ripa M, Bonora S, Lazzarin A; VEMAN Study Group.

Clin Microbiol Infect. 2015 May;21(5):510.e1-9. doi: 10.1016/j.cmi.2014.12.006. Epub 2014 Dec 11.

4.

Structured observations reveal slow HIV-1 CTL escape.

Roberts HE, Hurst J, Robinson N, Brown H, Flanagan P, Vass L, Fidler S, Weber J, Babiker A, Phillips RE, McLean AR, Frater J; SPARTAC trial investigators.

PLoS Genet. 2015 Feb 2;11(2):e1004914. doi: 10.1371/journal.pgen.1004914. eCollection 2015 Feb.

5.

Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.

Hasson H, Messina E, Merli M, Della Torre L, Morsica G, Bagaglio S, Lazzarin A, Uberti-Foppa C.

Int J Infect Dis. 2014 Dec;29:100-2. doi: 10.1016/j.ijid.2014.08.011. Epub 2014 Oct 24.

6.

HIV-1 DNA predicts disease progression and post-treatment virological control.

Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, Kinloch S, Cooper D, Schechter M, Tambussi G, Fidler S, Carrington M, Babiker A, Weber J, Koelsch KK, Kelleher AD, Phillips RE, Frater J; SPARTACTrial Investigators.

Elife. 2014 Sep 12;3:e03821. doi: 10.7554/eLife.03821.

7.

Orlistat-induced bullous leukocytoclastic vasculitis.

Lazic T, Fonder M, Robinson-Bostom L, Wilkel CS, Della Torre L.

Cutis. 2013 Mar;91(3):148-9.

PMID:
23617088
8.

Short-course antiretroviral therapy in primary HIV infection.

SPARTAC Trial Investigators, Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M, Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M, Kaye S, Gabriel M, Phillips R, Weber J, Babiker A.

N Engl J Med. 2013 Jan 17;368(3):207-17. doi: 10.1056/NEJMoa1110039.

9.

Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.

Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, Pedersen C, Okulicz JF, McClure M, Babiker A, Weber J, Fidler S; INSIGHT SMART and SPARTAC Investigators.

PLoS One. 2012;7(8):e43754. Epub 2012 Aug 31.

10.

Immune recovery and T cell subset analysis during effective treatment with maraviroc.

Cossarini F, Galli A, Galli L, Bigoloni A, Salpietro S, Vinci C, Della Torre L, Gianotti N, Spagnuolo V, Lazzarin A, Castagna A, Nozza S.

J Antimicrob Chemother. 2012 Oct;67(10):2474-8. doi: 10.1093/jac/dks216. Epub 2012 Jun 7.

PMID:
22678730
11.

Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection.

Hamlyn E, Hickling S, Porter K, Frater J, Phillips R, Robinson M, Mackie NE, Kaye S, McClure M, Fidler S; SPARTAC Investigators.

AIDS. 2012 Apr 24;26(7):887-90. doi: 10.1097/QAD.0b013e328351e721.

PMID:
22313951
12.

[Immigration, work and health--social, cultural and best practices in occupational medicine: the views of union patronage].

Bottazzi M, Della Torre L.

G Ital Med Lav Ergon. 2011 Apr-Jun;33(2 Suppl):29-32. Italian.

PMID:
22187920
13.

Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.

Nozza S, Galli L, Bigoloni A, Nicola G, Pogliaghi M, Cossarini F, Salpietro S, Galli A, Della Torre L, Tambussi G, Lazzarin A, Castagna A.

J Acquir Immune Defic Syndr. 2011 Apr;56(4):e113-5. doi: 10.1097/QAI.0b013e31820a9ae4. No abstract available.

PMID:
21350358
14.

[What usefulness in the simplifying of certification obligations of physicians?].

Brandi F, Cassina G, Ferioli A, Della Torre L, Guerreri MC.

Med Lav. 2007 Sep-Oct;98(5):434-5. Italian. No abstract available.

PMID:
17907537
15.

[Occupational diseases have decreased, they almost do not exist anymore].

Della Torre L.

Med Lav. 2001 Sep-Oct;92(5):353-4. Italian. No abstract available.

PMID:
11771355
16.

[We believe that most professional problems can be blamed on leadership problems].

Jensen CA, Aarås D, Kjølberg L, Alcoriza J, della Torre L, Tuscano O.

Sykepl Fag. 1993 Jun 15;81(3):51. Norwegian. No abstract available.

PMID:
8513356
17.

[A sampling study in 6 Lombardy hospitals on the knowledge possessed by nurses on the risks associated with accidental exposure to patient blood].

Arduini L, Di Giulio P, Franchi M, Nebuloni G, Pianosi G, Sisti P, Della Torre L, Valioni V, Ottone M.

Riv Inferm. 1989 Apr-Jun;8(2):84-92. Italian.

PMID:
2506631
18.

[Accidents in a factory of preserved meat products].

Della Torre L, Limonta F, Valsecchi F.

Med Lav. 1988 Jul-Aug;79(4):303-11. Italian. No abstract available.

PMID:
3231153
19.

Nonspecific interactions in dye binding to DNA. Influence of alcohols and amides.

Varani G, Della Torre L, Baldini G.

Biophys Chem. 1987 Dec;28(3):175-81.

PMID:
3440119
20.

[Evaluation of environmental risk and effects on health in a factory manufacturing polymethylmethacrylate sheets].

Della Torre L, Valsecchi F, Sala C, Cesana MA.

Lav Um. 1982 Sep-Oct;30(2):72-9. Italian. No abstract available.

PMID:
7183878

Supplemental Content

Loading ...
Support Center